The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Medications for Opioid Use Disorder Save Lives
Abstract
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already exist—like evidence-based medications—are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Testosterone suppression in opioid users: A systematic review and meta-analysis
Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., Daiter, J., Marsh, D. C., Steiner, M., Anglin, R., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.038 · Cited by 123 · cited 2×
“…major depressive and anxiety disorders as well as posttraumatic stress disorder (Grella et al., 2009; McHugh et al., 2013) and psychological distress (Back et al., 2010; Bawor et al., 2015; Manubay et al., 2015; McHugh et al., 2013); men have more comorbid alcohol and other SUDs and legal problems.”
Background
Cited by
Comparative effectiveness of different treatment pathways for opioid use disorder.
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20622 · Cited by 995
The changing opioid crisis: development, challenges and opportunities
Volkow, N. D., & Blanco, C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0661-4 · Cited by 522
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Neonatal Opioid Withdrawal Syndrome
Patrick, S. W., Barfield, W. D., Poindexter, B. B., COMMITTEE ON FETUS AND NEWBORN, C. O. S. U. A. P., Cummings, J., Hand, I., Adams-Chapman, I., Aucott, S. W., Puopolo, K. M., Goldsmith, J. P., et al. (2020) · Pediatrics · doi:10.1542/peds.2020-029074 · Cited by 363
Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K. M., Jones, C. M., & Cerdá, M. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103786 · Cited by 308
“Methadone, buprenorphine, and extended-release naltrexone are three FDA-approved medications for OUD (MOUD) that are consistently associated with improved health outcomes, including reduced opioid use, transmission of HIV and Hepatitis-C, and overdose risk (Leshner & Mancher, 2019).”
Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227966 · Cited by 291
Polysubstance use in the U.S. opioid crisis
Compton, W. M., Valentino, R. J., & DuPont, R. L. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00949-3 · Cited by 288
State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
Luo, F., Li, M., & Florence, C. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7015a1 · Cited by 166
The Epidemiology of Drug Abuse
Ignaszewski, M. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1937 · Cited by 100
Priest, K. C., Lovejoy, T. I., Englander, H., Shull, S., & McCarty, D. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05815-0 · Cited by 72
Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108764 · Cited by 67
Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl
Spadaro, A., Sarker, A., Hogg-Bremer, W., Love, J. S., O’Donnell, N., Nelson, L. S., & Perrone, J. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2032730 · Cited by 64
Clinical Management of Opioid Withdrawal.
Torres‐Lockhart, K. E., Lu, T. Y., Weimer, M. B., Stein, M. R., & Cunningham, C. O. (2022) · Addiction · doi:10.1111/add.15818 · Cited by 57
Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?
Dunphy, C., Peterson, C., Zhang, K., & Jones, C. M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108784 · Cited by 41
Bagley, S. M., Schoenberger, S. F., dellaBitta, V., Lunze, K., Barron, K., Hadland, S. E., & Park, T. W. (2023) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2022.08.026 · Cited by 33
Phillips, K. T., Stewart, C., Anderson, B. J., Liebschutz, J. M., Herman, D. S., & Stein, M. D. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108646 · Cited by 23
Zhang, K., Jones, C. M., Compton, W. M., Guy, G. P., Evans, M. E., & Volkow, N. D. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14001 · Cited by 22
Research, A. I. F., Latimore, A., Salisbury- Afshar, E., University of Wisconsin–Madison, Duff, N., National Academy of Medicine, Freiling, E., National Academy of Medicine, Kellett, B., Research, A. I. F., et al. (2023) · NAM Perspectives · doi:10.31478/202309b · Cited by 22
Medicaid Unwinding and Changes in Buprenorphine Dispensing
Constantin, J., Kenney, G. M., Simon, K., & Chua, K.-P. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.8469 · Cited by 16
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement
Karavitaki, N., Bettinger, J. J., Biermasz, N., Christ-Crain, M., Gadelha, M. R., Inder, W. J., Tsourdi, E., Wakeman, S. E., & Zatelli, M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae023 · Cited by 14
Powers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00347 · Cited by 15
US payment policy for medications to treat opioid use disorder: landscape and opportunities
McGinty, E. E., White, S. A., Eisenberg, M. D., Palmer, N. R., Brown, C. H., & Saloner, B. K. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae024 · Cited by 15
How Academic Medicine Can Help Confront the Opioid Crisis
Volkow, N. D., McLellan, T., & Blanco, C. (2022) · Academic Medicine · doi:10.1097/acm.0000000000004289 · Cited by 5
University, F. F., University, L. S., Mexico, V. C., Institute, M. G., & University, F. T. (2023) · Journal of Qualitative Criminal Justice & Criminology · doi:10.21428/88de04a1.d21bf9fc
Methadone and Suboxone® mentions on Twitter: Thematic and Sentiment Analysis (Preprint)
Chenworth, M., Perrone, J., Hogg, W., & Sarker, A. (2020) · doi:10.2196/preprints.19700
Metadata
- Authors
- Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Division, H. A. M., & National Academies of Sciences, E.
- Venue
- National Academies Press eBooks
- Publisher
- National Academies Press
- Published
- 2019-05-16
- OpenAlex
- W2991474708
- Cited by
- 715
- References
- 1
- FWCI
- 84.28
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.